
Respiratory infections Community acquired pneumonia: a review of common pathogens

Natalie Neu, MD MID 2009

Community acquired pneumonia: CAP

- 5.6 million cases annually = 8-15 per 1000 persons per year
- Very young and very old usually have highest rates of disease
 - Seasonal and geographic variation: WINTER!
- 3 groups for patient management Outpatient, inpatient (non- intensive care unit (ICU), and ICU
- Etiology:

 - Streptococcus pneumoniae (#1)
 "Atypical organisms"
 Viral (e.g. RSV, influenza, adenovirus)
 - Gram negative
 - Other



Pathogenesis

- · Lungs Defenses:
 - Innate (mucocilary escalator/phagocytes and acquired host defenses lungs-antibodies from vaccines)
- Why do you get CAP? - Alteration in host defenses, virulent organism or large innoculum
- How do you get CAP? - Micro-aspiration, hematogenous, contiguous spread, or macro-aspiration

CAP: general principles

- · Pathogenesis
- · Clinical presentation
- Diagnostic work up
- Specific organisms:
 - Bacteria (e.g. S. pneumoniae)
 - Viral (e.g. Influenza)
 - Fungi (e.g. Histoplasma)
 - Other (e.g. Mycobacterium tuberculosis)

Predisposing host conditions

- · Environmental: smoking, alcohalism (altered conscienciousness), toxic inhalations, travel/geographic
- Altered lung architecture/function: cystic fibrosis, chronic obstructive lung disease (COPD), immotile cilia syndrome, Kartagener's syndrome (ciliary dysfunction, situs inversus, sinusitis, bronchiectasis)
- Altered immune system: chemotherapy, • transplant, HIV, malnutrition, uremia, etc

Microbiology of CAP bacteria

- "Typical" organisms
 - S. pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Group A streptococci, Moraxella catarrhalis, anaerobes, and aerobic gram-negative bacteria.
- "Atypical" refers to pneumonia caused by Legionella spp, Mycoplasma pneumoniae, Chlamydophila (formerly Chlamydia) pneumoniae, and C. psittaci

| Condition | Commonly encountered pathogen(s) |
|--|---|
| Alcoholism | Streptococcus pneumoniae, oral anaerobes, Klebsiella pneumoniae, Acinetobacter species, Mycobacterium tuberculosis |
| COPD and/or smoking | Haemophilus influenzae, Pseudomonas aeruginosa, Legionella species, S. pneumoniae, Moraxella cara- rhalis, Chlamydophila pneumoniae |
| Aspiration | Gram-negative enteric pathogens, oral anaerobes |
| Lung abscess | CA-MRSA, oral anaerobes, endemic fungal pneumonia, M. tuberculosis, atypical mycobacteria |
| Exposure to bat or bird droppings | Histoplasma capsulatum |
| Exposure to birds | Chlamydophila psittaci (if poultry: avian influenza) |
| Exposure to rabbits | Francisella tularensis |
| Exposure to farm animals or parturient cats | Coxiella burnetti (Q fever) |
| HIV infection (early) | S. pneumoniae, H. influenzae, M. tuberculosis |
| HIV infection (late) | The pathogens listed for early infection plus Pneumocys- tis (inovenii, Cryptococcus, Histoplasma, Aspergillus, atypical mycobacteria (especially Mycobacterium kansai), R aeruginosa, H. influenzee |
| Hotel or cruise ship stay in previous 2 weeks | Legionella species |
| fravel to or residence in southwestern United States | Coccidioides species, Hantavirus |
| fravel to or residence in Southeast and East Asia | Burkholderia pseudomallei, avian influenza, SARS |
| Influenza active in community | Influenza, S. pneumoniae, Staphylococcus aureus, H. influenzae |
| Cough >2 weeks with whoop or posttussive vomiting | Bordetella pertussis |
| Structural lung disease (e.g., bronchiectasis) | Pseudomonas aeruginosa, Burkholderia cepacia, S. aureus |
| Injection drug use | S. aureus, anaerobes, M. tuberculosis, S. pneumoniae |
| Endobronchial obstruction | Anaerobes, S. pneumoniae, H. influenzae, S. aureus |
| n context of bioterrorism | Bacillus anthracis (anthrax), Yersinis pestis (plague), Francisella tularensis (tularensia) |

| Age | Organisms | |
|--------------------|--|--|
| Birth to 3 weeks | Group B Strepotococcal, Gram negative enteric bacilli, Cytomegalovirus, <i>Listeria monocytogenes</i> , HSV | |
| 3 weeks- 3 months | Chlamydia trachomatis, Respiratory syncycial virus (RSV), Parainfluenza virus type 3 (PIV), Streptococcus pneumoniae, Bordetella pertussis, Staphylococcus aureus | |
| 3 months - 5 years | RSV, PIV, influenza, adenovirus, rhinovirus, Streptococcus pneumoniae, Haemophilus influenzae Mycoplasma pneumoniae, Mycobacterium tuberculosis | |
| 5-15 years | Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus pneumoniae, Mycobacterium tuberculosis | |


Pneumonia: presentation and working up the etiology

- Common complaints

 Dyspnea, fever, cough (productive or not), chills, chest pain, myalgia, headache
- History
 - Age, co-morbidities, sick contacts, unusual exposures, social situation/support
- Physical exam findings
- Oxygen saturation
- Rales, tactile fremitus, decreased breath sounds, rhonchi Radiology

 Confirming the diagnosis; may or may not help narrow the diagnosis e.g. S. pneumonia: lobar; S. aureus: multilobar/abscess; Mycoplasma- diffuse interstitial

| pneumonia. | |
|---------------------|----------------------------------|
| Patient type | Etiology |
| Outpatient | Streptococcus pneumoniae |
| | Mycoplasma pneumoniae |
| | Haemophilus influenzae |
| | Chlamydophila pneumoniae |
| | Respiratory viruses ^a |
| Inpatient (non-ICU) | S. pneumoniae |
| | M. pneumoniae |
| | C. pneumoniae |
| | Legionella species |
| | Aspiration |
| | Respiratory viruses ^a |
| Inpatient (ICU) | S. pneumoniae |
| in patient (100) | Staphylococcus aureus |
| | Legionella species |
| | Gram-negative bacilli |
| | H. influenzae |






Streptococcus pneumoniae

- Gram-positive; oval or lancet-shaped, occur in pairs or short chains (diplococci)
- · Capsular polysaccharide is most important virulence factor; approximately 90 capsular types - Most common serotypes are 6, 14, 18, 19, and 23
- · Organism causes pneumonia, meningitis, otitis media, sinusitis, bacteremia, pericarditis, arthritis



From colonization to disease

- Adherence- cell wall proteins (phosphorylcholine) allow for adherence to receptor for platelet activating factor. Other binding sites include sialic acid and N-acetylgalactosamine b1-4 galactose - Faciliated by viral infections
- Secretory **IgA protease** inhibits function of secretory IgA which normally binds bacteria to mucin to facilitate clearance from the respiratory tract
- Capsule- antiphagocytic
- Invasion-cell wall, adhesins, and the cytotoxin pneumolysin- promotes intra-alveolar replication, penetration of pneumococci from the alveoli into the interstitium, and dissemination of the organisms into the bloodstream and cell death
- Host inflammatory response- cell wall (lipoteichoic acid) initiates alternative complement pathway, induce production of cytokines, nitric oxide (tissue damage), and PAF and initiate influx of neutrophils



Risk factors for pneumococcal pneumonia

- Alcohol, smoking, and asthma
- .
- Hyposplenism or splenectomy Immunocompromised (HIV, chemotherapy, etc)
- Others

Risk factors resistance to β -lactam antibiotics

- Age >65 Recently taking antibiotics within 3 months
- Alcoholism
- Immune suppression
- Multiple medical co-morbidities Exposure to child in daycare

S. pneumoniae

• Diagnosis

Blood culture

- (6-10% CAPs are bacteremia and 60% of these are S. pneumoniae)
- Urine antigen test
- Sputum culture
- Antimicrobial susceptibility testing is key especially
 - Penicillin: 60% susceptible, 20% intermediate, 20% resistant

Mycoplasma pneumonia

S. Pneumoniae treatment and prevention

- Treatment: Beta-lactam antibiotics
 - PCN Resistance classified by breakpoints
 - Meningitis (only a fraction of plasma concentration gets in to CSF);
 - Sensitive MIC ≤ 0.6
 - Intermediate MIC 0.1-1 mcg/ml
 - Resistant MIC ≥ 2 mcg/ml
 Non-meningitis pneumococcal disease
 - Susceptible MIC ≤2 mcg/mL
 - Susception MIC MIC Intermediate MIC = 4 mcg/mL
 - Intermediate MIC =4 mcg/mL
 Resistant MIC ≥8 mcg/mL
 - Cephalosporins, vancomycin, macrolides, linezolid
- Prevention: Vaccines
 - ention: vaccines
- Conjugated pneumococcal vaccine (Prevnar[®])
 23 valent pneumococcal vaccine (Pneumovar[®])
- 23 valent pneumococcal vaccine (Pneumovax[®])

Mycoplasma

- Does not have a cell wall
- Cell membrane contains sterols not present in other bacteria
- Special enriched media needed for growth
- Laboratory cultures rarely done- diagnosis usually by serology (IgG)
- PCR testing not routinely available
- · Bedside test- cold agglutinins

Clinical scenario 2

- Myra is a 21 year old medical student living in the dorm room studying for exams
- She goes to student health complaining of low grade fever, headache, non-productive cough, sore throat and general malaise
- Her exam reveals mild fine inspiratory ralesnothing impressive
- The Dr sends her for an xray that reveals bilateral infiltrates

Mycoplasma- pathogenesis and immunity


- <u>Toll-like receptor 2</u> important for binding to respiratory epithelium
- <u>P1- protein attachment factor</u>- facilitates attachment to sialic acid receptors of respiratory epithelium and RBC surface
- Remains extracellular
- Causes local destruction of cilia, interferes with normal airway clearance which leads to mechanical irritation and persistent cough
- Acts as a super antigen stimulating PMS's and macrophages to release cytokines (TNFα, IL1, and IL 6)

A common atypical pneumoia "Walking pneumonia"

- · Lacks seasonal pattern, spread by droplet secretions
- Common in children and young adults
 7-20% of CAP especially for non-hospitalized cases
- Mild respiratory symptoms
- Complications: otitis media, erythema multiforme, hemolytic anemia, myocarditis, pericarditis, neurologic abnormalities
- Treatment: macrolides (erythromycin, azithromycin, clarithromycin) or fluoroquinolones (levofloxacin)

C. trachomatis xray





Chlamydophila (Chlamydial) pneumonias: trachomatis, pneumoniae, psittaci

- Intracellular parasites- use host high energy phosphate compounds
- Trilaminar outer membrane which contains LPS
- Two phase life cycle- Elementary body (infectious) and reticulate body (divides by binary fission in the host)

Clinical scenario 3


- JM 10 week old infant born to a 16 year old mom
- Pregnancy history limited due to lack of prenatal care but baby born full term, no complications, left hospital 2 days
- Seen by pediatrician at 2 weeks old with eye discharge was given eye drops
- Returned to ER: RR 60, cough but no fever
- Xray done and bloods drawn

Chlamydophila pneumonias

- Infect non-ciliated columnar cells
- Multiply in alveolar macrophages
- Perivascular and peribronchiolar infiltrates
- Clinical symptoms due to host immune response
- Immunity not long-lasting
- Diagnosis by serology- four fold rise in titer

C. trachomatis pneumonia

- Neonatal infection presents at 1-3 months of age
- Staccato-like cough, rapid respiratory rate
- NO FEVER
- Evaluation: minimal chest findings, xray hyperinflation and diffuse infiltrates, peripheral eosinophilia
- Treatment: erythromycin
- Prevention: maternal screening



C. pneumoniae

- Single strain- TWAR
- Prolong incubation period
- Common in school age children and elderly (over 65)
- Indolent course-sore throat, chronic cough, no fever
- Chest xray variable (lobar, diffuse, bilateral)
- Diagnosis: PCR and serology
- Treatment: macrolide, doxycycline, levofloxacin


Clinical scenario 4

- Charlie is a 68 year old retired plumber who recently underwent a renal transplantation
- Felt great and was tinkering around his house updating his bathroom fixtures
- Came for follow up visit complaining of high fever, cough, chills and his wife said that he was acting confused at times
- Laboratory studies reveal WBC 35,000 with left shift, LDH >1000
- Chest xray reveals multilobar process

C. psittaci

- History: Parrot exposure
- Mild clinical respiratory symptoms, fever, rash
- Concomitant symptoms: cns- headache, confusion, cranial nerve palsy, seizures; hepatitis; pericarditis
- Xray-consolidation, reticular nodular pattern, adenopathy
- Titers: > 1:64 diagnostic
- Treatment: doxy, tetracycline, erythromycin





Legionella: pathogenesis and immunity

- Aspiration or inhalation of organism
- Flagellae and pili allow attachment to respiratory epithelium and macrophages
- Trafficking within cell due to dot (defective organelle trafficking) and icm (intracellular multiplication) genes which allow the organism to evade phagosome-lysosome fusion
- Intracellular replication facilitated by intracellular multiplication locus (Lgn-1) and by Mip
- Virulence factors: exotoxins, including a hemolysin, cytotoxin, deoxyribonuclease, ribonuclease, and various proteases cause destruction by killing the infected respiratory cells leading to formation of microabscesses
- Immunity primarily cell mediated immunity (T cells) (inhibited by glucorticoids and immune suppressive agents e.g. transplant medications

The 1976 Legionnaire's Convention, Philadelphia, PA

- 29/180 patients died due to pneumonia
- · Identification of a gram negative bacilli
- Epidemiologic link to being in the lobby of Hotel A; historical link to 1966 outbreak in a psychiatric hospital
- National panic- worries about biologic and chemical warfare- media frenzy
- 6 months to identify the organism

Legionnaires disease

- Incubation period up to 10 days
- Clinical- influenza like illness or severe manifestation= pneumonia
- Fever (105), rigors, cough, headache
- Multilobular infiltrates and microabscesses
- Extrapulmonary manifestations: CNS, diarrhea, abdominal pain, nausea
- High white counts, abnormal liver, renal panel
- High mortality-15-20% depending on host

Legionella pneumophila and micdadei


- 2-6% community acquired pneumonias
- Risk: immunocompromised, hospitalized, and outbreak situations
- Gram negative bacilli- don't stain with common reagents
- 50 species and 70 serogroups- most common L. pneumophila and most common serogroups 1,4, 6
- Fastidious and grow on supplemented media
- Organisms contaminate water sources: air conditioning systems and water tanks


Legionella: Diagnosis, prevention and treatment

- Urine antigen detection assays- EIA for *L. pneumophila* only
- Serology >1:128 positive however late development of antibodies
- · Culture on special media
- Treatment: macrolide or levofloxacin
- Prevention: hyperclorination, super heating, continuous copper-silver ionization

Clinical scenario 5 (Loyola Univ Medical Center)

- Jerry, a 7 month old child, comes to clinic with a running nose, sneezing and slightly irritable
- Diagnosed with URI
- Returns 2 weeks later because he is turning blue with coughing spells. Spells are worse at night, seems to have spasms and then he "whoops" for air.
- Examination reveals mildly dehydrated, not distressed, clear lung exam
- WBC reveals leucocytosis with lymphocytosis







Bordetella pertussis "Whooping cough"


- Fastidious, gram negative coccobacilii
- Pertussis, parapertussis, and bronchiseptica
- Spread by respiratory droplets
- Rapid multiplication in mucus membrane
- No bacteremia
- Toxins cause local tissue damage

Pertussis

- Affects children under 1 and adults with waning immunity
- Three stages of disease:
 - Catarrhal
 - Paroxysmal
 - Convalescent










- Special media- Bordet-Gengou- blood, charcoal, and starch. Nasopharyngeal culture
 Serologic testing: acute and convalescent titers
 PCR testing
- Treatment- decrease symptoms and transmission- best if early in disease
 - Erythromycin or Macrolide (better tolerated, shorter course)
 - Alternative for some: trimethoprim-sulfamethoxazole

• Prevention

- Antimicrobial prophylaxis- close contacts and high risk individuals Vaccination- during childhood and booster vaccine for those over 18 (Tdap)

G protein and ADP riboyslation Host cell



| Toxin production and pathophysiology | | | |
|---------------------------------------|---|--|--|
| Pertussis toxin-↑ CAMP | ↑ secretions (paroxysmal stage) | J J J J J J J J J J J Prelinentificare | |
| Adenylate cyclase and hemolysin toxin | Inhibit WBC chemotaxis, phagocytosis, and killing | And a | |
| Heat-labile toxin | Local tissue destruction | Andread and and and and and and and and and a | |
| Tracheal cytotoxin | Destroys ciliated cells, IL-1 (fever), NO (kills epithelial cells) | | |
| Lipid A and Lipid X | Activate alternative complement, cytokine release | 2010 State Perturbation Medidia tooli Adeepkerysteritooli | |

Summary: Community acquired pneumonia CAP

- Understand historical elements, physical examination finding and exposures relative for CAP
- Inpatient or outpatient management - Perform diagnostic tests
- Empirical antimicrobial therapy
- Prevention: smoking cessation, vaccination, etc

